NAO vs Gise 2026
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
NAO
This medical app helps healthcare professionals determine the appropriate dosage and prescription for new oral anticoagulants (NOACs) like dabigatran, rivaroxaban, apixaban, and edoxaban. It focuses on adult patients with non-valvular atrial fibrillation and at least one risk factor for stroke.
- NOAC prescriber identification
- Dosage calculation
- Dabigatran, Rivaroxaban, Apixaban, Edoxaban
- Adult patients with AFib
- Stroke risk factor assessment
Read full descriptionHide full description
I nuovi anticoagulanti orali rappresentano una valida alternativa alla terapia con warfarin nella prevenzione di ictus ed embolia sistemica in pazienti adulti con fibrillazione atriale non valvolare con almeno uno dei fattori di rischio per ictus. Attualmente i NAO approvati in Europa e negli Stati Uniti sono dabigatran, rivaroxaban, apixaban e edoxaban. Questa applicazione consente di identificare la prescrivibilità e la posologia di dabigatran, rivaroxaban, apixaban e edoxaban in pazienti adulti con fibrillazione atriale non valvolare.
Gise 2026
Read full descriptionHide full description
GISE 2026 is the app for GISE 2026 National Congress activities. You can browse the complete scientific program by day, topic and room, create your own personal program and vote during poll sessions.
Screenshots
Verdict
The clearest difference is iOS requirement: NAO at 6.1 against Gise 2026's 15.0. On price, update cadence, ads and in-app purchases there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
Both ship on a similar rhythm, roughly every 2 months. The most recent releases landed on November 1, 2026 and October 14, 2026 respectively.
| Parameter | NAO | Gise 2026 |
|---|---|---|
| Price | Free | Free |
| Positive reviews | 100.0% of reviews | — |
| Update frequency | Every 2 months | Every 2 months |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | — |
| Devices | iPhone, iPod | iPhone, iPad, iPod — better |
| Requires iOS | 6.1 — better | 15.0 |
| Further details — not scored | ||
| Size | 4 MB | 71 MB |
| Age rating | 17+ | 17+ |
| Developer | ANMCO(ASSOCIAZIONE NAZIONALE MEDICI CARDIOLOGI OSPEDALIERI) | Tecnoconference |
In-app purchases
NAO
No in-app purchases
Gise 2026
No in-app purchases
